Expertise in
9
conditions

Dr. Mary D. Chamberlin

Dartmouth-Hitchcock Clinic
Lebanon, NH
Expertise in
9
conditions
Specialties:Oncology | Hematology
Accepting New Patients
Offers Telehealth
Expertise in
9
conditions
OverviewInsuranceLocationsClinical Research

Overview

Mary Chamberlin is an Oncologist and a Hematologist in Lebanon, New Hampshire. Dr. Chamberlin is highly rated in 9 conditions, according to our data. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Chamberlin is currently accepting new patients.

Her clinical research consists of co-authoring 39 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in VT
Hospital Affiliations
Mary Hitchcock Memorial Hospital
Alice Peck Day Memorial Hospital
Cheshire Medical Center
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Anthem
  •  Humana

Locations

DARTMOUTH-HITCHCOCK CLINIC
1 Medical Ctr Dr, Lebanon, NH 03756
603-650-5000
Other Locations
DARTMOUTH-HITCHCOCK CLINIC
590 Court St, Keene, NH 03431
603-354-5400

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer
Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 17, 2025
Intervention Type: Procedure, Other, Radiation, Drug
Study Drug: Paclitaxel
Study Phase: Phase 2
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Randomized, Controlled Trial to Determine the Effects of an Exercise Intervention on Physical Activity During Chemotherapy for Patients With Early Stage Breast Cancer
A Randomized, Controlled Trial to Determine the Effects of an Exercise Intervention on Physical Activity During Chemotherapy for Patients With Early Stage Breast Cancer
Enrollment Status: Completed
Publish Date: August 21, 2020
Intervention Type: Behavioral
Study Phase: Not Applicable
Phase 1b Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
Phase 1b Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
Enrollment Status: Withdrawn
Publish Date: March 12, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

39 Total Publications

Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylation.
Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylation.
Journal: bioRxiv : the preprint server for biology
Published: October 10, 2024
Similar Doctors
Expertise in
38
conditions
Dr. Frederick N. Lansigan
Hematology Oncology | Hematology | Oncology
Expertise in
38
conditions
Dr. Frederick N. Lansigan
Hematology Oncology | Hematology | Oncology

Dartmouth-Hitchcock Clinic

1 Medical Ctr Dr, 
Lebanon, NH 
603-650-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Frederick Lansigan is a Hematologist Oncology specialist and a Hematologist in Lebanon, New Hampshire. Dr. Lansigan is highly rated in 38 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), T-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Lansigan is currently accepting new patients.

Expertise in
62
conditions
Dr. James M. Nickerson
Oncology | Hematology
Expertise in
62
conditions
Dr. James M. Nickerson
Oncology | Hematology

Dartmouth-Hitchcock Clinic

289 County Rd, 
Windsor, VT 
 (14.5 mi)
802-674-6711
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Nickerson is an Oncologist and a Hematologist in Windsor, Vermont. Dr. Nickerson is highly rated in 62 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Non-Hodgkin Lymphoma, Chronic B-Cell Leukemia (CBCL), and Bone Marrow Aspiration. Dr. Nickerson is currently accepting new patients.

Expertise in
16
conditions
Dr. Keisuke Shirai
Hematology Oncology | Palliative Medicine | Oncology
Expertise in
16
conditions
Dr. Keisuke Shirai
Hematology Oncology | Palliative Medicine | Oncology

Dartmouth-Hitchcock Clinic

1 Medical Ctr Dr, 
Lebanon, NH 
603-650-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Keisuke Shirai is a Hematologist Oncology specialist and a Palliative Medicine provider in Lebanon, New Hampshire. Dr. Shirai is highly rated in 16 conditions, according to our data. His top areas of expertise are Melanoma, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Lung Adenocarcinoma. Dr. Shirai is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile